Celltrion, Inc.

Industry

  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • OTC, Consumer
    • Generic Drugs

Other Names/Subsidiaries

  • Bio CDMO
  • Celltrion Asia Pacific PTE
  • Celltrion Biopharma
  • Celltrion Europe
  • Celltrion Global Safety Data Centre
  • Celltrion Group Hong Kong
  • Celltrion Healthcare Hungary Kft
  • Celltrion Pharm
  • Celltrion Pharma USA
  • Shanghai Vcell Biotech
  • Vcell Healthcare
See more in Biomedtracker

Latest on Celltrion, Inc.

Generics Bulletin

Celltrion Plans Multiple US Biosimilar Launches In An ‘Exciting And Momentous’ Year

 
• By Dave Wallace

If Celltrion’s US biosimilars business was already picking up speed, then that momentum is only going to continue in 2025, according to Celltrion USA’s chief commercial officer Thomas Nusbickel. In an

Scrip

LigaChem Eyes Future Acquisition Of IKSUDA Following 26.6% Stake

 
• By Jung Won Shin

Leading South Korean antibody-drug conjugate (ADC) specialist LigaChem Biosciences has made a $25m investment for an initial 26.6% equity stake in existing partner IKSUDA Therapeutics, and secured the

Scrip

Korea Needs To Think Bigger On M&As: KHIDI

 
• By Jung Won Shin and Kosh Naran

Mergers and acquisitions usually happen in major global biopharma markets as a way to gain new technologies, R&D or commercial portfolios, expand a business or to beef up supply networks. But in S

Generics Bulletin

Celltrion Keeps Pace With Ustekinumab Discounts As It Launches US Stelara Rival

 
• By Dave Wallace

Celltrion has become the latest firm to enter the US market for Stelara (ustekinumab) biosimilars, with its Steqeyma (ustekinumab-stba) version representing the sixth rival to the $10bn brand to be